Health and Human Services Secretary Alex Azar issued the following statement on the Food and Drug Administration’s announcement of two guidances regarding drug manufacturers’ use of shared risk evaluation and mitigation strategies:

“HHS is taking more action on President Trump’s blueprint to put American patients first. The FDA’s announcement today will help generic drug manufacturers bring low-cost competition to market faster and discourage brand-name companies’ misuse of laws meant to protect public health. Greater competition in drug markets is one of the key pieces of our plan to bring down drug prices. HHS will continue taking action to promote competition, building on accomplishments like the record number of generic drugs the FDA has approved under President Trump.”